Iambic to Participate in September Investor Conferences

SAN DIEGO--(BUSINESS WIRE)-- Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced its participation in the following September investor conferences:

• Cantor Global Healthcare Conference - Sept. 3-5, 2025
• Citi Global TMT Conference - Sept. 3-5, 2025
• Bank of America Healthcare Trailblazers - Sept. 17, 2025

About Iambic’s AI-Driven Discovery Platform

The Iambic AI-driven platform was created to address the most challenging design problems in drug discovery, leveraging technology innovations such as Enchant (multimodal transformer model that predicts clinical and preclinical endpoints) and NeuralPLexer (best-in-class predictor of protein and protein-ligand structures). The integration of physics principles into the platform’s AI architectures improves data efficiency and allows molecular models to venture widely across the space of possible chemical structures. The platform enables identification of novel chemical modalities for engaging difficult-to-address biological targets, discovery of defined product profiles that optimize therapeutic window, and multiparameter optimization for highly differentiated development candidates. Through close integration of AI-generated molecular designs with automated chemical synthesis and experimental execution, Iambic completes design-make-test cycles on a weekly cadence.

About Iambic Therapeutics

Iambic is a clinical-stage life-science and technology company developing novel medicines using its AI-driven discovery and development platform. Based in San Diego and founded in 2020, Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters. The Iambic platform has demonstrated delivery of new drug candidates to human clinical trials with unprecedented speed and across multiple target classes and mechanisms of action. Iambic is advancing a pipeline of potential best-in-class and first-in-class clinical assets, both internally and in partnership, to address urgent unmet patient need. Learn more about the Iambic team, platform, pipeline, and partnerships at Iambic.ai

View source version on businesswire.com: https://www.businesswire.com/news/home/20250902721761/en/

[email protected]

Source: Iambic Therapeutics

You May Also Be Interested In

• Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Ca
• Exploring the Reventador Volcano: JETOUR G700 and Ed Stafford Redefine the Adventure Experience
• Valerio Therapeutics and Etherna Immunotherapies Progress Towards Finalisation of Transaction Documentation Regarding the Contemplated Acquisition